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which is very similar to that of humans; human and 
mouse genomes are approximately 85% identical. fur-
thermore, mice are easy to reproduce and to maintain 
and relatively inexpensive to breed. however, in some 
cases, mouse models have failed to be predictive.1 for 
example rodent models, correctly predicted human tox-
icity in only 43% of the cases when considering a big 
comparative study to test the concordance between tox-
icity of pharmaceuticals in humans and animals.2 The 
maximum tolerated dose (MTd) of drugs in mice is 
higher than in humans, so it was be necessary to evalu-
ate drugs by using doses comparable to patients. More-
over, despite successful preclinical testing, only 15% of 
in the last years several advances have been made toward understanding the biology of cancer. in par-
ticular it has been observed that although many patients 
have the same type of cancer their tumors harbor differ-
ent molecular alterations. This has led to the concept of 
personalized therapy and the development of advanced 
techniques of preclinical imaging and new mouse mod-
els of disease. Preclinical imaging allows mapping of 
disease markers in vivo and in some cases also receptor 
targeted therapy.
at the same time mouse models of disease represent 
a direct link from in vitro studies to clinical trial in pa-
tients. Mice have a well-characterized genetic pattern, 
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or overexpressed. This method allows the study of the 
effects of these genetic alterations over time and to as-
sess the therapeutic response of these tumors enabling 
the identification of the genetic basis of therapeutic re-
sponse. one of the advantages of these models consists 
of the fact that these animals have an intact immune sys-
tem. Several anticancer therapies today are based on the 
stimulation of the immune system of patients, leading 
their immune system to eradicate tumors.5 also an accu-
rate geMM model, compared with xenografts models 
often mimics much better human cancer histologically. 
This structural difference of the tumor, affects the re-
sults of drug therapies, and also the effects of response 
to therapy.6 in these models also, it is possible to study 
the stage of the disease and to test different drugs at dif-
ferent stages of the tumor development. Mouse models 
can often be expanded to more subjects in which it is 
possible to test different pharmaceutical compounds.
however, geMM models also have several disad-
vantages: usually it is difficult to drive the extensive 
genetic alterations that occur in human cancer. het-
erogeneity can exist also within the same tumor, and 
often geMM models show heterogeneity in the same 
cancer model. These facts do not help developing tar-
geted therapies, and often researchers find effective an-
titumor molecules in mouse models that do not translate 
efficiently in human settings. Furthermore, the devel-
opment of geMM models often requires longer time 
periods, and not all mice at the end develop pathologi-
cal features of the tumor disease. for example among 
the TRβPV/PV mouse models of follicular thyroid carci-
noma (fTc) only those homozygously deleted of the 
TRβPv gene develop 100% of follicular thyroid tumor 
after 5 months, while heterozygous mice do not develop 
cancer.7 finally, these models do not always reproduce 
faithfully the specific pathways of development and 
progression of the human disease state such as angio-
genesis and metastasis occurrence.
using geMM as a part of co-clinical trial remains 
currently challenging. first of all there is the necessity 
to establish cooperation between hospitals and research 
centers specializing in handling these mouse models. it 
is in fact necessary to have an adequate facility to engi-
neer the mouse models, to analyze their genetic materi-
al, and it is also very important to establish a preclinical 
imaging laboratory to perform the in vivo analyses of 
tumor biomarkers, the radiochemistry of targeted drugs 
early clinical trial succeed and also very few drugs are 
approved for clinical study by the food and drug ad-
ministrations (FDA). On the other side, the efficiency 
of translational models could be increased when used 
together with emerging translational approaches like 
advanced preclinical molecular techniques. The aim of 
this review was to illustrate some emerging models of 
disease that allow patient tumor implantation in mice 
for subsequent drug testing and advanced approaches 
for therapy mediated by preclinical imaging. in par-
ticular we will describe targeted therapy mediated by 
high frequency ultrasound and magnetic resonance, two 
emerging techniques in molecular preclinical therapy.
Mice models for personalized cancer treatment
a thorough study of the human genome allows the 
characterization and separation of patients based on 
their genetic defects and the classification of subgroups 
of tumors that have the best chance of survival based on 
several prognostic factors. according to that, patients 
can be stratified between those who respond better to 
one therapy rather than to another. Because it is not 
always easy to perform human clinical trials based on 
cost and difficulties in patient recruitment, a new real-
ity is emerging consisting of co-clinical trials performed 
at the same time on patients and on murine models of 
disease.
currently, there are two personalized mouse models 
of disease: the genetically engineered mouse models 
(geMM) of cancer and patient derived tumor xenograft 
models (PdX). These models are now used in most hos-
pital for co-clinical trials to guide therapy in ongoing 
human patient trials.
GEMM mouse models used in co-clinical trial
geMM models are used as part of phase i/ii trials 
in humans for drug development.3, 4 during these tri-
als there is a comparison and integration between data 
obtained both in mouse and humans. The identification 
of the genetic basis of therapeutic response obtained in 
mouse models is important for patient stratification in 
clinical trial. The concept is based on geMM cancer 
mouse models in which the genetic profile is modified 
so that one or more genes that are involved in the trans-
formation process or malignancy are mutated, deleted 
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ful to test the potential resistance of target pathways. it 
is also possible to generate from the tumor of a single 
patient different avatar systems to simultaneously test 
several therapeutic approaches. Most cancers present a 
large number of mutations, and there is often more than 
one potential therapeutic approach for a single patient. 
PDX models are useful not only for the identification of 
drug targets but also to determine predictive biomark-
ers of disease or resistance. After first engraftment of 
a tumor in a mouse, the tumor is propagated through 
several generations (f0 to f3). Therapeutic agents are 
usually tested in f3; however, the use of further propa-
gated tumor generations may be problematic. in fact 
during the passage through several generations, mouse 
stromal components may become dominant, so that the 
loss of the human tumor elements could create limita-
tions in testing therapies. in PdX of non-small cell lung 
cancers, some authors tested the efficiency of three of 
the most commonly used drugs in first line chemother-
apy. These authors developed a first generation NSCLC 
subrenal capsule xenografts, which where suitable for 
quick assessment (6-8 weeks) of the chemosensitivity 
of patients’ cancers and selection of the most effective 
regimen in the clinics.10
Some other authors showed instead a combined ap-
proach of exome sequencing/bioinformatic analysis to 
verify the presence of somatic mutations and person-
alized xenografting to define therapy.11 in these clini-
cal studies, patients underwent conventional treatment 
while they tested the new therapy in a mouse avatar, 
according to specific mutations found in the patients. 
Therapy was then made available to the patients select-
ed for personalized therapy. Patients having colorectal, 
pancreatic cancer, glioblastoma, nSclc, and mela-
noma were enrolled in this study, in which half of the 
patients received treatment according to results of the 
exome sequencing and the treatment on mice models. 
in most cases patient treatment was based exclusively 
on the avatar mouse, where patients achieved a partial 
remission or a stable disease. also this study had its 
limitations. in fact, patients’ tumor xenografts do not 
always grow in immune compromised mice, and tumor 
engraftment efficacy may depend on the type of tumor. 
for some tumors, such as certain melanomas, lung and 
colorectal cancers, transplant efficiency can reach ≥75% 
with a time of tumor growth within few month. how-
ever, these rates depend on sample size and sample type 
with contrast agents of Magnetic resonance, hfuS, 
radiotracers for PeT or SPecT, and also to have avail-
able a dedicated mouse pathology facility. furthermore, 
as suggested by nardella et al. it is also very useful to 
be able to use comparative pathology centers (cPc) to 
support co-clinical trials in close consultation with the 
clinicians.4
ideally, a closer collaboration between Physicians 
and Veterinary doctors aiming at testing new drugs in 
the most efficient manner would accelerate the transla-
tion of new therapeutic discoveries to human medicine. 
an example of a co-clinical trial was the study on the 
mutation of KraS in mice models of non-small cell 
lung cancer (nSclc). This study was designed to de-
termine if the MeK inhibitor selumetinib (aZd6244) 
could increase the efficacy of docetaxel, a standard-
of-care chemotherapy for nSclc. Pharmacodynamic 
studies, including positron-emission tomography (PeT) 
and computed tomography (CT), identified biological 
markers in mice and patients that provided a rationale 
for the differential efficacy of these therapies in the dif-
ferent genotypes.8
in another phase ii trial with nSlc harboring EML4-
ALK fusion, the authors tested both in mice and patients 
the alK inhibitor crizotinib against the standard-of-
care cytotoxic agents docetaxel or pemetrexed. They 
showed that also in mice, crizotinib enhanced the over-
all survival in mice compared to the standard-of-care 
treatment.9 The authors demonstrated the superiority 
of crizotinib to chemotherapy in alK-rearranged non-
small cell lung cancer and predicted strategies to over-
come resistance.
PDX models used in co-clinical trial
PdX models also known as mouse “avatar” have 
been recently used as a part of several co-clinical trials. 
PdX models could be very useful when patients are not 
in a state of good health to be enrolled in clinical trials 
or there is not an ongoing clinical trial for that patient. 
The concept is based on the fact that by implanting a 
patient tumor (biopsy or an excised tumor) in a mouse, 
it is possible to study a specific drug response and to 
test personalized therapy. it is possible in this way to 
predict either the efficacy or the lack of efficacy of the 
various pharmacological agents or other therapy strate-
gies for an individual patient. PdX models are also use-
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viral delivery system for gene transfer both in vivo and 
in vitro, encapsulated in commercially available ultra-
sound contrast agents (microbubbles).16-18 The Micro-
bubbles (MBs) are able to entrap and to protect the viral 
vectors from the immune system.19 The MBs are gas 
filled microsphere formed with a compatible shell com-
posed of lipid, protein or polymers, capable of acting as 
ultrasound contrast agents. uS contrast agents are de-
livered intravenously and can pass through the smallest 
of the vessels without obstacles because they typically 
range between 0.5 to 8 micron in size, and they contain 
high-molecular weight gases with less solubility and 
diffusivity, which improves MBs persistence allowing 
passage through the microcirculation (figure 1).16-20
MBs have also been studied for their bursting be-
havior in response to destructive ultrasound for mea-
surement of blood flow parameters and for drug and 
gene delivery. ultrasounds help the delivery of genes 
in two ways. In the first place, the acoustic energy of 
uS causes the transient opening of cell membranes, a 
process known as sonoporation. Sonoporation due to 
positive and negative pressure phases, produces pores 
in cell membranes facilitating the transport of genetic 
material through cell membranes, which are otherwise 
impenetrable.21 in the second place, ultrasound causes 
the oscillation of MBs and rupture of the shell (cavita-
(e.g. pieces collected by surgery, biopsy, fine needle as-
pirate), tumor origin, and conservation of the patients’ 
samples.12 Therefore, the development of the avatar 
model is expensive, and could require up to 6 months. 
another limitation is related to the tumor microenvi-
ronment. implanting a tumor subcutaneously does not 
reproduce the same microenvironment in which the ex-
planted tumor was growing, and in xenografts models 
only few tumors metastasize. a good alternative to the 
subcutaneous xenografts model is to create an ortho-
topic model, which consists of implanting the tumor in 
the same organ of tumor origin, reproducing a similar 
tumor microenvironment to the original one.13 further-
more, this model often reproduces naturally the same 
metastatic process of the human disease.14
another limit in the use of the PdX models is rela-
tive to the fact that these mice do not have an intact im-
mune system; therefore, they are not useful to study the 
reaction of the immune system during anticancer treat-
ments, which often could be helpful to better understand 
therapeutic mechanisms. PdX models are of limited use 
in screening immune mediate agents such as vaccines, 
immune modulators (anti-Pd1) or agent activating the 
immune system like anti-cd40 antibodies. Today sev-
eral strategies have been developed to modulate im-
mune function in mice, for example one is to transplant 
purified human CD34+ hematopoietic stem cells into 
myeloblasted nSg/nog recipients (BlT mouse strain 
developed by Jackson laboratories). another way to re-
construct the immune system of a mouse and to use it 
for personalized medicine is to aspirate from the bone 
marrow of individual cancer patients hematopoietic 
stem cells and to inject them into the recipient mouse.15
Advanced therapy with ultrasound 
and microbubbles
The principle of gene therapy is to introduce genes or 
nucleic acids into cells to cure genetic defects. in par-
ticular, the success of gene therapy has been obtained 
with the use of viral vectors. in fact, viral vectors re-
main the best vehicles to introduce genes into cells for 
their ability to efficiently transfer genes with sustained 
and robust expression. however, systemic administra-
tion of viruses is thwarted by innate and adaptive an-
tiviral immune responses. To circumvent this problem, 
it was demonstrated a unique intravenous site-specific 
figure 1.—Schematic diagram and comparison of nanoparticles’ and 
microbubbles’ composition.
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safe and effective method to selectively deliver genes to 
target cells.
ultrasound contrast agents have become important for 
their ability to directly provide the various classes of bio-
active substances to a number of tissues, and they have 
become more and more popular for the targeted delivery 
of genes and for the administration of drugs. The system 
has been widely used in preclinical studies to enhance 
gene expression in a site-specific manner in a variety of 
organs. This technique offers advantages of high safety 
and allows to control spatially and temporally the ef-
fects of sonoporation in order to improve the localized 
tissue deposition of gene complexes (figure 2). in fact, 
the MBs are destroyed only when they pass through the 
ultrasound beam for which the destruction site of MBs 
can be controlled by modulating the characteristics of the 
ultrasound field. In addition, direct deposition in the path-
ological site increases the effectiveness of the drug and 
reduces the effects associated to the systemic delivery.
an interesting application of gene delivery mediated 
by uS is the eradication of human prostate tumor resis-
tant to treatment.17 gene therapy is a promising strategy 
for the treatment of this tumor. The prostate gland is 
available by ultrasound and potential therapeutic genes 
can be directed to this organ using ultrasound after a 
simple intravenous injection. Prostate cancer (Pc) is 
one of the most common cancers and is the second lead-
ing cause of death in men in the uSa. advanced Pc 
is most commonly resistant to conventional anti-cancer 
treatments because it frequently overexpresses the anti-
apoptotic protein Bcl-2 and or Bcl-xl.
a secreted cytokine, that has broad-spectrum, cancer-
selective and apoptosis-inducing properties that inhibits 
growth of Pc cells, is the mda-7/IL-24 gene. intratu-
moral injection of mda-7/IL-24 associated to a replica-
tion-incompetent adenovirus (ad.mda-7) inhibited the 
growth of Pc in immune-incompetent animals.
in contrast, Ad.mda-7 showed to be ineffective in 
prostate cancer cells that overexpress Bcl-2 and/or Bcl-
xl, however intratumoral injection of a conditionally 
replication-competent adenovirus (crca) (a cancer 
terminator virus-cTV), expressing mda-7/IL-24 caused 
growth arrest and apoptosis of the therapy resistant Pc 
cells implanted in nude mice.
it has been shown that the MBs are the best candidates 
for the delivery of these genes. in fact, the complex MB/
Ad.mda-7 targeted in du-145 cells using ultrasound has 
tion), which causes the release of the genetic material 
from the MBs at the target site in a controlled manner.21 
in particular, the behavior of the microbubbles depends 
on the amplitude of ultrasound applied. at very low 
acoustic power (Mechanical index <0.05-0.1), micro-
bubbles oscillate in a relatively symmetrical and linear 
manner, and this produces ultrasound scattering equal to 
the transmitted frequency. at a slightly higher mechani-
cal index of 0.1-0.3, the microbubbles become some-
what more resistant to compression than to expansion 
and they oscillate in a non-linear manner, backscatter-
ing a variety of frequencies. higher acoustic pressures 
(Mechanical index >0.3-0.6) destroy the microbubbles 
with diffusion of the gas via large shell defects or by 
complete fragmentation.
So, ultrasounds improve both the permeability of the 
target cells and the release of genetic material from the 
microbubbles.
The possibility of introducing microbubbles intrave-
nously is a great advantage compared to using more in-
vasive delivery procedures.
Several strategies have been developed to promote 
targeting of ultrasound contrast agents to specific re-
gions of diseases’; however, all strategies may be 
grouped in two major approaches: passive targeting and 
active targeting.
Passive targeting exploits the chemical and electro-
static properties of the microbubbles’ shell, resulting in 
the arrest of the MBs within the microcirculation. This 
method is based on up-regulation of receptors that bind 
non-specifically albumin or lipid components of the mi-
crobubble shell. Passive targeting does not exhibit mo-
lecular specificity, but allows a functional imaging of 
the pathophysiological condition that induces the over 
expression or up-regulated cell surface biomarkers.
active targeting, on the other hand, is based on the 
attachment of specific antibodies or other ligands on the 
surface of the microbubbles. This leads to the accumu-
lation of contrast agent targeted to specific sites due to 
the use of adhesion ligands able to recognize antigens 
peculiar to the disease. Potential ligands include anti-
bodies, peptides, and polysaccharides.
With growing understanding of the molecular mech-
anisms underlying genetic diseases, gene therapy has 
been proposed as an effective approach. currently, the 
main obstacle of the clinical application of gene therapy 
is not the lack of an ideal gene, but rather the lack of a 
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a subsequent study has shown the further devel-
opment of this effective treatment for prostate can-
cer resistant to therapy in combination with radiation 
therapy.18, 21 These findings highlighted the therapeutic 
potential of this new image-guided gene transfer tech-
nology in combination with radiation therapy in patients 
with prostate cancer resistant to treatment.
another study in 2012 investigated whether the out-
burst of the microbubbles using ultrasound could be 
used to improve the delivery of sirna directed to the 
reduced the tumor implanted in nude mice. in addition, 
the delivery of MB/cTV guided by ultrasound has com-
pletely eradicated not only the cancer du-145/Bcl-XL 
resistant to therapy but also distant tumors that were not 
targeted by the ultrasound.
Therefore, the MBs by enclosing the adenoviruses in 
a gas-filled core allowed on one hand the protection of 
the virus from rapid degradation by the immune system 
and on the other hand to increase through ultrasound the 
delivery specificity of the Ads to the tumor.
a B
c
figure 2.—ultrasound images of tumor xenografts and whole body 
bioluminescence following specific delivery of Adeno-Luciferase (Ad.
luc) using microbubble/ultrasound-mediated gene transfer.
a) ultrasound image of tumor xenograft before tail vein injection of 
microbubble/ad.luc complexes; ultrasound image of tumor xenograft 
following tail vein injection of microbubble/ad.luc complexes; B) 
whole body bioluminescence imaging of a mouse at 48-hours postde-
livery of ad.luc using microbubble/ultrasound-mediated gene transfer, 
demonstrating the specific localization of luciferase signal to the tar-
geted tumor xenograft.
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sues; also their delivery is based on the ePr (enhanced 
permeability and retention) effects requiring hours or 
days for maximum accumulation. Since it is difficult 
to predict their in vivo absorption due to a number of 
factors such as the heterogeneity of the vascular bed, 
the tumor microenvironment, and the presence of infil-
trating macrophages; the clinical importance of the ePS 
effect has been the subject of several recent scientific 
discussions.
for all these reasons nanocarriers of smaller size 
compared to microbubbles have been introduced as 
transport vehicles and delivery system for drugs (figure 
1). These nanocarriers in addition to target specific cells 
and tissues are able to preserve the biological activity of 
the drug during transportation. The nanocarriers have 
small dimensions and with long lifetimes of circula-
tion, and display advantageous properties for diagnos-
tic and therapeutic applications. They are able to cross 
the capillary walls and the walls of cell membranes to 
deliver the drug, thereby reducing side effects and in-
creasing curative index. in addition these nanocarriers 
can be coated with specific ligands to adhere to the tar-
get tissue, thereby promoting intracellular uptake of the 
drug after insonation. although the delivery system of 
the drug mediated by ultrasound is a very advantageous 
technique, there are several challenges still to be over-
come. While the nanocarriers must be small in order to 
travel through the bloodstream, on the other side they 
must be large enough to prevent renal excretion, and 
stable to prevent the content from being released before 
application of the ultrasound pulse.24
Several nanocarriers were introduced and evaluated, 
including organic and inorganic materials. The fam-
ily of nanocarriers includes polymeric nanoparticles, 
nanoemulsions, liposomes and micelles; recently also 
many inorganic materials are used as nanocarriers such 
as metal nanoparticles and nanocarriers based on car-
bon.
Polymeric nanoParticles
Polymeric nanoparticles include nanospheres and 
nanocapsules. The polymers mostly used for the deliv-
ery of drugs/genes consist of poly (lactic acid) (Pla), 
poly(e-caprolactone) (Plc) and poly(lactic-co-glycolic 
acid) (Plga), these showed best properties of encap-
sulation and controlled release of the in vitro content.25 
egf receptor (egfr) in murine squamous cell carcino-
mas.22 The inhibition of the epidermal growth factor 
receptor (egfr) is an established strategy for treating 
different types of cancers such as lung cancer, colorec-
tal cancer and squamous cell carcinomas (Scc). Sev-
eral pharmaceutical agents that can block the pathway 
of egfr signaling like the monoclonal antibody cetux-
imab and the kinase inhibitor gefitinib have been de-
veloped. however, these molecules often are unable to 
block the pathway. for this reason, in 2012 other strate-
gies such as rna interference (gene silencing mecha-
nism) have been explored to inhibit egfr signaling. 
direct injection of sirna (short interference rna) 
may seem appealing; however, rnase may impair its 
action. for this reason microbubbles were used as a ve-
hicle for egfr sirna. In vitro and in vivo studies were 
conducted to confirm down-regulation of EGFR by this 
delivery system. In vitro the microbubbles loaded with 
egfr-sirna and delivered to murine squamous carci-
noma cells, reduced both egfr expression and growth 
of egf-dependent cells compared to control. In vivo the 
delivery of microbubbles, loaded with egfr-sirna 
and delivered to squamous cell carcinomas, decreased 
egfr expression and tumor doubling time compared to 
control cells that instead received microbubbles loaded 
egfr-sirna, but without ultrasound or microbubbles 
loaded control sirna and ultrasound. These results 
bear great promise for the future development of thera-
pies based on direct gene delivery to tissues.
Nanocarriers in ultrasonic therapeutic systems
drug resistance is a major obstacle for cancer curative 
chemotherapy. for this reason, in recent years, targeted 
therapy appeared to be a promising therapeutic choice 
for cancer treatment. The general approach is to develop 
vectors capable of locally releasing the drug/gene fol-
lowing the development of internal or external stimuli 
such as light, heat, and ultrasound. imaging of the tumor 
should be performed before and during the release of 
the stimulus and also the biodistribution of the carrier is 
monitored through imaging to optimize the time of the 
release of the stimulus.23 Microbubbles are commonly 
used as probes for intravascular ultrasound imaging and 
are becoming more popular tools for targeted drug de-
livery. however, due to their size microbubbles could 
remain confined to vessels and poorly reach tumor tis-
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tidylcholine, a natural phospholipid that contains a phos-
phate group linked to a hydrophobic section. liposomes 
are commonly prepared using the method called “film 
hydration”: the various components are combined co-
dissolving the lipid in an organic solvent. Subsequently, 
the organic solvent is removed from the vacuum de-
position of the films. When all the solvent is removed, 
the mixture of solid lipid is hydrated using an aqueous 
buffer. lipids immediately swell to form liposomes. li-
posomes are effective carriers of drugs; their multifunc-
tional characteristics can be obtained by modifying the 
lipid composition of the shell (double layer). liposomes 
have low immunogenicity, good biocompatibility and 
degradability, and are often used as a shell for nano-
bubbles. compared to materials coated with polymers 
(polymer-coated materials), the liposomal nanocarriers 
improve the intensity of the imaging signal. in a study 
by Piao et al. human serum albumin-coated nanopar-
ticles with lipid-hSa lnPs were prepared to contain 
sirna (hSa-lnPs-sirna). The nanoparticles were 
loaded with phrgfP-targeted sirna. The study showed 
a significantly reduced expression of phrGFP mRNA by 
hSa-lnPs-sirna in phr-gfP Mcf7, Mda-MB-231 
and SK-Br-3 transfected cells with respect to con-
trol. in a phrgfP-transfected Mcf-7 tumor xenograft 
model, tumor fluorescence was decreased after IV ad-
ministration of hSa-lnPs-sirna at a dose of 3 mg/kg 
compared to sirna alone. hSa-lnPs-sirna showed 
a superior pharmacokinetic profile compared to control 
sirna at a dose of 1 mg/kg. These results demonstrated 
that hSa-lnPs could be considered a new non-viral 
carrier that can be used for delivery of sirna in tumor 
cells of the breast.28
micelles
a micelle consists of a series of amphiphilic sur-
factant molecules aggregated spontaneously in water, 
forming a spherical vesicle. The “core” of the micelle is 
hydrophobic and it may contain hydrophobic drugs. a 
micelle is defined by its molecular size and other char-
acteristics of the surfactants. Polymeric micelles formed 
from poly (ethylene oxide) -b-poly (propylene oxide), 
poly (ethylene oxide) -b-poly (ester) and poly (ethylene 
oxide) -b-poly (amino acids) have great promise for the 
delivery of drugs.29 Several studies have demonstrated 
the efficacy of ultrasound-mediated delivery of drugs/
compared with natural polymers, synthetic polymers 
have better purity and reproducibility. according to 
different needs, their structure can be changed to engi-
neer nanoparticles that may avoid the immune system 
surveillance. for example copolymerized polymeric 
nanoparticles with polyethylene glycol (Peg) can avoid 
recognition by the phagocytic mononuclear cells. The 
polymeric shell may also improve the stability of nano-
carriers and increase their ability to resist the ultrasound 
pressure field.
recent research has developed preparations of hybrid 
compounds with metals and/or active principles, allow-
ing the use of nanoparticles as theranostic agents. The 
metals commonly used include gold, iron, silver, and 
gadolinium. Such theranostic agents can be used both 
to diagnose and monitor treatment response of cancer 
using magnetic resonance imaging (Mri) and to deliver 
encapsulated therapeutic agents.
Perfluorocarbon nanoemulsion
The family of liquid perfluorocarbons (PFCs) in-
cludes Perfluorodecalin (PFD), Perfluorooctyl bro-
mide (Pfob), Perfluorohexane (PFH), Perfluoropentane 
(PFP), Perfluorotributylamine (PFTBA) and Perfluoro-
15-crown-5-ether (PFCE). The PFCs are fluorinated 
compounds initially used in clinics as gas/oxygen car-
riers and today are considered as contrast agents for 
echography, magnetic resonance imaging and targeted 
therapy. a Pfc nanoemulsion is prepared starting from 
a mixture of hexane and pentane perfluorinated, the 
nanoemulsion is formed because of the self-assembly 
properties of the polymer and when the solvent is re-
placed. The PFC particles can infiltrate the arterial 
walls, cross the internal elastic lamina, and bind and lo-
calize molecular epitopes in intramural tissues. Similar-
ly, Pfc nanoparticles targeted for angiogenesis markers 
have been used successfully to detect neovasculariza-
tion around tumors implanted in athymic mice using 
ultrasonic scanners.26
liPosomal nanocarriers
The liposomes (vesicles in double lipid layer) are col-
loidal structures consisting of a mixture of phospholip-
ids and cholesterol in aqueous solution.27
The major component of the lipid bilayer is phospha-
Th
is
 d
oc
um
en
t i
s 
pr
ot
ec
te
d 
by
 in
te
rn
a
tio
na
l c
op
yr
ig
ht
 la
w
s.
N
o 
ad
di
tio
na
l r
ep
ro
du
ct
io
n 
is 
au
th
or
ize
d.
It 
is
 p
er
m
itt
ed
 fo
r 
pe
rs
on
al
 u
se
 to
 d
ow
n
lo
ad
 a
nd
 s
av
e
 o
n
ly 
on
e 
file
 a
nd
 p
rin
t o
nl
y 
on
e 
co
py
 o
f t
hi
s 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 m
ak
e
 a
dd
itio
na
l c
op
ie
s
(ei
the
r s
po
rad
ica
lly
 o
r s
ys
te
m
at
ica
lly
,
 
e
ith
er
 p
rin
te
d 
or
 e
le
ct
ro
ni
c) 
of 
the
 A
rtic
le
 fo
r 
a
ny
 p
ur
po
se
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 d
ist
rib
u
te
 th
e 
el
ec
tro
ni
c 
co
py
 o
f t
he
 a
rti
cl
e 
th
ro
ug
h 
on
lin
e 
in
te
rn
e
t a
nd
/o
r i
nt
ra
n
e
t f
ile
 s
ha
rin
g 
sy
st
em
s,
 
e
le
ct
ro
ni
c 
m
ai
lin
g 
or
 a
ny
 o
th
er
m
e
a
n
s 
w
hi
ch
 m
ay
 a
llo
w
 a
cc
e
ss
 to
 th
e 
Ar
tic
le
.
Th
e 
us
e 
of
 a
ll 
or
 a
ny
 p
ar
t o
f t
he
 A
rti
cl
e 
fo
r 
a
ny
 C
om
m
er
cia
l U
se
 is
 n
ot
 p
er
m
itt
ed
.T
he
 c
re
at
io
n 
of
 d
er
iva
tiv
e
 w
o
rk
s 
fro
m
 th
e 
Ar
tic
le
 is
 n
ot
 p
er
m
itt
ed
.T
he
 p
ro
du
ct
io
n 
of
 re
pr
in
ts
 fo
r 
pe
rs
on
al
 o
r c
om
m
er
cia
l u
se
 is
n
o
t p
er
m
itt
ed
.I
t i
s 
no
t p
er
m
itt
ed
 to
 re
m
ov
e,
 
co
ve
r,
 
ov
e
rla
y, 
o
bs
cu
re
,
 
bl
oc
k,
 o
r c
ha
ng
e 
an
y 
co
py
rig
ht
 n
ot
ice
s 
or
 te
rm
s 
o
f u
se
 w
hi
ch
 th
e 
Pu
bl
is
he
r m
ay
 p
os
t o
n 
th
e 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 fr
a
m
e
 o
r 
u
se
 fr
a
m
in
g 
te
ch
ni
qu
es
 to
 e
nc
lo
se
 a
ny
 tr
a
de
m
ar
k,
 lo
go
,
o
r 
o
th
er
 p
ro
pr
ie
ta
ry
 in
fo
rm
a
tio
n 
of
 th
e 
Pu
bl
is
he
r.
greco adVanceS in Molecular Preclinical TheraPy MediaTed By iMaging
84 The QuarTerly Journal of nuclear Medicine and Molecular iMaging March 2017
porphyrin-lipid around a perfluoropropane gas. The gas 
provides contrast ultrasound images while the porphy-
rin gives the shell fluorescent and photoacoustic proper-
ties.34
When these multimodal microbubbles are subjected 
to low-frequency ultrasound, the porphyrin microbub-
bles (pMB) implode to nanoparticles (pnP) with a di-
ameter between 5-500 nm. The resulting nanoparticles 
retain the photoacoustic and fluorescent properties; 
these properties make it possible to demonstrate the real 
conversion of the pMB to pnP.
in particular, the pMB are exposed to 1 Mhz, high-
duty-cycle (50%), ultrasonic (2 W cm-2), named as 
“conversion uS” in 2 sec pulses and characterized after 
sonication with zero, one, three or ten pulses. after ten 
pulses, most of the pMB are converted into pnP. This 
conversion is possible in tumor-bearing mice using pho-
toacoustic imaging. in fact, the resulting pnP penetrate 
preferentially in tumor tissues highlighting them with 
optical and photoacoustic imaging.
The specific mechanism that drives the conversion of 
the multimodal microbubbles from micro to nano, has 
yet to be studied, in addition the conversion is specific 
to pMB. conventional microbubbles formed by a shell 
of phospholipids without the attached porphyrin group, 
after sonication with “uS conversion”, form nanostruc-
tures similar to the pnP, but this nanostructures do not 
display any therapeutic function due to the absence of 
the porphyrin component.
The pnP based on porphyrin have proven interest-
ing for imaging and treatment of diseases, especially 
for cancer, due to their multifunctional nature. The pres-
ence of the porphyrin has transformed a conventional 
microbubble from the unimodal ultrasound contrast 
agent and delivery vehicle, without any function after 
the ultrasound mediated outburst, to a trimodal con-
trast agent with both imaging and therapeutic proper-
ties (theranostic). These considerations introduce a new 
theranostic strategy in a research and health care field 
that is constantly evolving such as cancer management.
A further refinement of this technique will be to pro-
duce nanoparticles in which the high therapeutic and di-
agnostic payloads within the pM will generate smaller 
sized nanoparticles to increase the delivery efficiency of 
the image-guided drug.
innovative design of microcarriers for drug or gene 
delivery to overcome biological barriers.
genes using micelles as carriers for the treatment of tu-
mors in vivo. diaz de la rosa et al. have prepared na-
nomicelle of loaded drug with a diameter of about 10 
nm.30 husseini et al. have prepared nanomicelle loaded 
of drugs by co-incubating nanomicelles and anticancer 
drugs, reducing the side effects of chemotherapy.24 it 
has also been shown that copolymers micelles as Peo-
PPo (PPo-Peo-block copolymers) are more secure, 
and kinetically stable with better capacity of solubiliza-
tion than regular micelles.31, 32 despite these advantag-
es, Peo-PPo-block copolymers still suffer from limita-
tions such as low stability and short residence time; all 
factors that limit their application.
albumin nanoParticles
albumin is an excellent carrier that can be used for 
drug delivery. it is promising for being non-toxic, non-
immunogenic, highly biocompatible and easily biode-
gradable. albumin nanoparticles have been measured 
with dynamic light scattering method to have a 100 
nm diameter. They have gained more and more impor-
tance for their high release drug capacity and to elicit 
almost no side effects. Michaelis et al. have developed 
nanoparticles of human serum albumin (hSa-nP) using 
nanoparticles of apolipoprotein-e, which could cross 
the blood-brain barrier with loperamide (which exerts 
an antinociceptive effect).33 apo-e has been shown to 
mediate transfer of drugs across the blood-brain bar-
rier. apolipoprotein-e has been associated with hSa-
nP nanoparticles loaded with loperamide by means 
of a chemical method. using the haS-nP/loperamide 
nanoparticles, immediately after their intravenous in-
jection, it was observed an antinociceptive effect in icr 
mice; demonstrating that the nanoparticles have crossed 
the blood brain barrier.33
a different approach to the traditional drug delivery 
is the use of ultrasound to implode the microbubbles in 
nanoparticles.34 conversion from micro to nano allows 
both carriers to bypass the ePr effect, using an external 
trigger, and both to penetrate more easily the tissue bar-
riers due to their small size. in this way, nanoparticles, 
filled with drugs, first penetrate the diseased tissue and 
then release the drug when the core is converted into a 
gas.
huynh et al. at the university of Toronto have cre-
ated multimodal microbubbles incorporated in a shell of 
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enzymes, causes damage to the microbubbles’ payload 
especially if it consists of genetic material. a strategy 
to prevent the degradation of the payload is the incor-
poration of membrane peptides destabilizing like inf7, 
h5Wy and gala inducing endosomal escape 41 or the 
incorporation of cationic peptides such as poly-ethylene 
imine (Pei) that instead guide the therapeutic agent re-
lease from the endosomal compartment.
The last obstacle is represented by the drug efflux 
pumps that confer multidrug resistance (Mdr) be-
cause they excrete the drug upon entry into the cell. To 
circumvent this, microcarriers coupled with inhibitors 
of drug efflux pumps have been developed which are 
more cytotoxic making them more effective than con-
trol microcarriers.42
however, in spite of all the improvements in the de-
sign of these microcarriers, if all of the biological bar-
riers that a drug encounters during its delivery are not 
considered when designing a microcarrier, drug deliv-
ery systems will continue to fail in their clinical appli-
cation. only a better understanding of the biological 
processes that regulate these barriers will allow both 
the development of more appropriate carriers and better 
site-specific delivery.
Ultrasound at low-intensity for cancer therapy
In recent years, the preclinical field established four 
new techniques for cancer therapy, such as sonody-
namic therapy, ultrasound mediated chemotherapy, 
ultrasound-mediated gene delivery and antivascular 
ultrasound therapy.43 unlike the techniques previ-
ously described, these techniques utilize low-intensity 
ultrasound.44 in each therapeutic modality, theranostic 
contrast agents composed of microbubbles pose both a 
therapeutic role and a diagnostic/imaging role. The de-
velopment of these agents is important because it estab-
lishes a therapeutic-diagnostic platform that is useful to 
monitor the success of anti-cancer therapies.
There is no clear definition of low-intensity ultra-
sound, but generally it corresponds to an intensity less 
than 5.0 W cm-2, equivalent to a root-mean-square 
pressure amplitude of about 0.3 MPa.
The insonation of tumors with low-intensity ultra-
sound is easy to perform, because it does not require a 
focused beam, the apparatus is not expensive, and the 
effects on adjacent normal cells are minimal. The dif-
The advantages shown by micro and nanocarriers 
for drug delivery have opened new avenues for site-
specific delivery of bioactive drugs.35 The microcarriers 
are considered safe and tolerable vehicles, but despite 
these features, these carriers face a number of sequen-
tial biological barriers that limit their site-specific bio-
availability and thus adequate therapeutic results. These 
obstacles include opsonization and subsequent seques-
tration by the mononuclear phagocyte system (MPS), 
non-specific distribution, blood vessels flow limitations, 
cellular internalization, and drug efflux pumps.
it is necessary, for an innovative design to take into 
account all the biological barriers that microcarriers 
may meet following intravenous administration.
innovative designs, such as the use of non-traditional 
geometries to improve vascular dynamics or function-
alization with biomimetic membranes to prevent the 
uptake of phagocytes, have shown several advantages 
with respect to conventional carriers 35.
first, the microcarriers are subject to opsonization 
and sequestration by MPS, resulting in increased ac-
cumulation in organs such as the spleen and liver, and 
contributing to a non-specific distribution in healthy or-
gans. Several strategies have been used to “camouflage” 
the microcarriers such as Pegylation, which provides a 
hydrated surface that hinders the formation of a protein 
corona prolonging the circulation lifetime of microcar-
rier/drug complexes from minutes to hours,36 or conju-
gation of the self cd47 peptide on their surface so that 
macrophages identify them as self and avoid phagocy-
tosis.37 finally, coating with cell membranes extracted 
from autologous leukocytes or red blood cells that pro-
vide instead a biomimetic surface, thereby avoiding up-
take from macrophages.38
Because the dynamic flow in blood vessels, and adhe-
sion properties, microcarriers are all heavily dependent 
on their geometry and size.39 Several scientists studied a 
non-spherical design of the microcarriers for drug deliv-
ery. in fact, numerous discoveries have shown that non-
spherical particles under a flow show dynamic rolling 
and tumbling, compared to spherical ones that flow at a 
certain distance parallel and away from the vessel wall.40
even cellular internalization proves to be a formida-
ble barrier. indeed endocytosis of microcarriers leads to 
their invagination in the membrane and the formation of 
intracellular vesicles, which fuse with lysosomes. The 
high acidity of the lysosome environment, also rich in 
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neovascularization can be detected by ultrasound us-
ing microbubbles to differentiate vascular from avas-
cular regions within the tumor.45 after intravascular 
injection, the vascularized regions are accessed using 
a B-mode image of routine and power doppler. in this 
case, the combination of ultrasound and microbubbles 
was used to damage tumor vasculature causing cell ne-
crosis and subsequent reduction of the tumor mass. in 
several studies of murine melanoma models, it has been 
shown that the use of ultrasound on the tumor in the 
presence of microbubbles has a significant antivascular 
effect.46-50 The predominant effect of insonation, in the 
different studies, was the irreparable dilatation of tumor 
capillaries with intracellular edema. in particular, every 
minute of insonation decreased perfusion of the tumor 
by about 25%, which was followed by necrosis of the 
neoplastic cells. interestingly, in these theranostic stud-
ies, the vascularization in adjacent normal tissues was 
not affected by the ultrasound treatment. in these stud-
ies it was noted that the action of ultrasound antivascu-
lar low-intensity was increased when the insonation oc-
curred at 3 Mhz than that at 1 Mhz and the temperature 
of the tumor increased by 5 °c.min-1 and 2 °c.min-1.48 
The main biological effect recorded on endothelial cells 
is the thermal effect. In fact, blood flow in tumor vessels 
is slower than normal vessels causing further interac-
tions between ultrasound and microbubbles resulting in 
damage caused increased temperature to the endothelial 
cell coatings. The damage is less in normal capillaries, 
where circulation is faster and any increase in tempera-
ture is smaller and has no biological effect.
Besides the thermal effect also cavitation of the micro-
bubbles is a biophysical interaction mechanism. Stud-
ies using continuous waves of ultrasound emphasize 
the creation of thermal effects while pulsed ultrasound 
determines cavitation. While it is difficult to separate 
the two effects, both play a role. low-intensity ultra-
sound with continuous waves cause the oscillation of 
microbubbles with long intervals leading to significant 
heating effects. high-intensity ultrasound with shorter 
pulses instead yields the collapse of the microbubbles 
causing an inertial cavitation.
antivascular ultrasound therapy offers some advan-
tages but it also has several limitations. The advantage 
is that the effect is generic and not specific to any type 
of cancer. antivascular ultrasound requires access to the 
endothelial cell surface unlike drugs that should instead 
ference with high-intensity ultrasound is that times of 
treatment are longer.
The four aforementioned techniques produce bioef-
fects that induce the death of cancer cells, and we will 
focus our attention on sonodynamic therapy and anti-
vascular ultrasound therapy.
sonodynamic theraPy
Sonodynamic therapy (SdT) is derived from pho-
todynamic therapy. While in photodynamic therapy, 
photosensitizers are excited by light to produce reac-
tive oxygen species, SdT uses ultrasound to produce 
cavitation and to induce sonosensitizers to produce free 
radicals that kill cancer cells rapidly growing.
an important development of SdT is the combina-
tion of sonosensitizers with microbubbles contrast 
agent. The combination of sonosensitizers with mi-
crobubbles contrast agent creates a theranostic agent; 
because through the microbubbles, loaded into the tu-
mor vasculature, the agent can be monitored using ul-
trasound imaging, and once it is detected in the site of 
interest sonodynamic therapy can be initiated. in addi-
tion to cytotoxic effects, other possible effects on tumor 
growth have also been evaluated, such as thermal effect 
and antivascular ultrasound.
in recent years, considerable data have been pub-
lished using different sonosensitizers applied to differ-
ent types of tumors, although several studies must still 
be performed to assess the effectiveness of the different 
sonosensitizers that have been developed so far.
To date, studies of SdT have been performed only 
in small laboratory animals implanted with subcutane-
ous tumors; future studies should be performed in larger 
mammals before it will be tested in phase-i human clin-
ical studies.
antivascular ultrasound theraPy
antivascular ultrasound therapy also uses microbub-
bles as theranostic agents.
it has been hypothesized that a solid tumor should be 
constituted by at least two cellular compartments; one 
containing the neoplastic cells, and the other contain-
ing the endothelial cells from tumor neovascularization. 
unlike normal tissues, tumor tissues have a fragile vas-
cularization and abnormal branching patterns. Tumor 
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as to release drugs, when subjected to a high frequency 
magnetic field.56, 58 The MnPs show enhancing proper-
ties in Mri scans, in the tissues where they accumulate, 
due to the presence of magnetic elements either in their 
shell or in the core, which causes the shortening of T1 
or T2 relaxation times.55, 59 The MnPs accumulate in 
target tissues through: 1) passive targeting; 2) active 
targeting; and 3) targeting due to an external magnetic 
field.53 Passive targeting takes advantage of the lack 
of architecture of blood vessels that characterize most 
solid tumors. This phenomenon is called “enhanced 
permeability and retention” (ePr), and, because of this 
effect, molecules larger than 40 kda accumulate in the 
tumor, while avoiding healthy tissues.60 active target-
ing is based on molecules bound on the nPs surface, 
which recognize tumor-selective receptors, in order to 
exploit their anticancer proprieties in the target tissue 
and to prevent systemic side effects.53, 61 Targeting with 
an external magnetic field combines active targeting 
with the magnetic field ability of concentrating the NPs 
in the tumor lesion.53
in the following paragraphs, the state of the art about 
MnPs theranostic applications for cancer therapy will 
be discussed.
MRI nanoparticles and anticancer drugs
chemotherapy is one of the most commonly used 
approaches against cancer. The main issues of chemo-
therapy in cancer therapy are the systemic effects that it 
produces, i.e. damage to healthy tissues and/or systemic 
side effects. In order to construct a specific drug deliv-
ery system able to bypass body barriers, and to elude 
drug degradation, magnetic nPs capable of incorporat-
ing several chemotherapies such as Paclitaxel, doxoru-
bicin (doX), and gemcitabine (geM) have been de-
veloped.55
These nanotechnology-based drug delivery systems 
have minimized the distribution of chemotherapies in 
normal tissues and allowed their delivery beyond the 
body barriers in the target tissues.60 for example, in brain 
tumors the presence of the blood-brain barrier (BBB) 
as well as the expression of drug efflux pumps doesn’t 
allow the passage of many anti-cancer molecules.62 
for example, poly – (methacrylic acid) – polysorbate 
– 80-grafted-starch has been developed as a nanother-
anostic system that allows doX delivery across BBB 
penetrate. a limitation of antivascular ultrasound is that 
susceptible tumor neovasculature has to be present for 
the therapy to be effective.
antivascular ultrasound therapy is very powerful but 
it remains to clarify the mechanism of interaction of dif-
ferent intensities of ultrasound. additionally, it should 
be optimized so that the disrupting effects on the vas-
culature are maximized while minimizing damage to 
adjacent normal tissues.
MRI nanoparticles for theranostic applications
drugs available for cancer treatment are not com-
pletely effective; hence researchers have been prompted 
to look for new therapeutic strategies. The main limita-
tions of drugs currently used in clinical oncology are: 
1) non-specific molecular targeting of cancer cells; and 
2) systemic toxicity.51 in recent years, in an attempt to 
overcome such limitations, a new frontier for pharma-
cological studies has been identified in the preclinical 
imaging of animal models of human oncologic diseases. 
Moreover, the gap between diagnosis and the beginning 
of treatment is another factor that reduces therapeutic 
efficacy. Theranostics describes any material or sub-
stance able to exert a therapeutic effect in the target tis-
sue while simultaneously diagnosing the pathology by 
imaging. nanotheranostics exploits nanotechnology for 
treating and monitoring disease in real-time.52 nanopar-
ticles (nPs) are solid colloidal particles ranging in size 
from 1 to 1,000 nm, and are usually classified on their 
size, shape, charge and surface chemistry.53, 54 in ther-
anostics, the nPs can be “organic” (e.g. lipids, proteins, 
polymers) or “inorganic” (magnetic and non-magnetic 
nPs).53, 54 among the potentials of nPs are: the possi-
bility to include within the core or in the outer structure 
contrast agents and/or a therapeutic cargo, to function-
alize them with targeting elements, and, for some nano-
materials, to be used for thermal therapy.54
Magnetic resonance imaging (Mri) is a powerful tool 
used in diagnostic imaging, and it offers the advantages 
of a high spatial resolution, the absence of ionizing ra-
diation, and the production of tomographic images.55 
Theranostic applications of Mri for cancer therapy are 
based on magnetic nPs (MnPs), approximately of 10 
to 100 nm, which display the double function of imag-
ing contrast agent and anticancer therapy.56, 57 in fact, 
they are able to induce cell death by heating, as well 
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free drugs, as well as a better enhancement than clinical 
contrast agents.65 furthermore, the Pegylated surface 
of nPs offers greater retention time within the tumor.65
MRI nanoparticles for photothermal therapy
Photothermal therapy (PTT) is an anti-cancer treat-
ment that uses heat production through different sourc-
es, such as: radiofrequency, high-intensity focused ul-
trasonography, microwave, alternating magnetic field, 
and laser.69 The PTT must be supported by valid meth-
ods to identify the tumor location, to monitor therapy in 
real time, and to evaluate the effectiveness of treatment 
after therapy.70 PTT uses near infrared (nir) laser ir-
radiation to heat nPs and selectively kill the cells that 
incorporated nPs. Several strategies have been devel-
oped to bridge together cancer PTT and multimodal im-
aging.56
MoS2 is a graphen-like nanomaterial used for PTT 
due to its high nir absorption ability.71 a dual Mri/
Photoacoustic tomography (PaT) system has been used 
to realize effective magnetic targeted photothermal ab-
lation of cancer while performing imaging diagnosis in 
vivo, with a complex of MoS2 and fe3o4 nPs.71 com-
bining ultrasonography, laser irradiation and Mri, gold 
nanoshelled nPs have been used to obtain effective 
thermal ablation in tumor bearing mice with a precise 
focus on tumor location.70
among the compounds that have displayed the best 
outcome in the context of PTT, is WS2-io@MS-Peg, 
in which WS2 nanosheets, pre-adsorbed on their surface 
with ionPs, are coated with a mesoporous silica shell, 
on to which Peg is attached. This system has been test-
ed in tumor bearing mice, and drug delivery and thermal 
ablation efficacy has been evaluated, demonstrating no 
toxic effects.67
dual metal-organic-frameworks (Mofs) nPs, with 
Prussian blue core, represent one of the most innova-
tive systems that combine imaging with drug delivery 
performance. This compound can be used both as Mri 
imaging contrast and as fluorescence optical imaging 
contrast. furthermore, it can be loaded with anticancer 
drugs, performing both chemotherapy and PTT.72 The 
effectiveness of combined drug delivery and PTT has 
been also assessed using carbon nanomaterials, such 
as graphene oxide (go). due to its optical absorption 
propriety, the go can combine both photodynamic and 
for brain metastases therapy, since free doX is not able 
to penetrate the BBB, and this system is also able to co-
incapsulate gd-dTPa as a Mri contrast agent.62
Magnetic iron oxide nanoparticles (ionPs) combines 
imaging contrast properties with drug delivery capabili-
ties, overcoming the tumors’ intrinsic barriers.57 The 
complex of ionPs and gemcitabine (geM), combined 
with the natural ligand of uPar expressed in pancreatic 
cancer, has been demonstrated to inhibit tumor growth 
in a xenograft mouse model of pancreatic cancer.57 The 
properties of Super Paramagnetic iron oxide (SPio) 
nPs as surface charge, magnetic assets and size, make 
SPio optimal not only for cancer detection, but also 
for the release of drugs and gene therapy.55 When SPio 
nPs are administrated in vivo by intra-vascular injec-
tion, they accumulate in the tumor mass by the ePr ef-
fect, and they are able to bypass drug resistance mecha-
nisms such as P-glycoprotein efflux pump.63 The SPio 
can be loaded with different types of chemotherapies 
for the treatment of oncological diseases in vivo.64 drug 
biodistribution can be studied combining therapeutic 
agents with SPio in a polymeric vehicle.52
in order to stabilize nPs under physiological con-
ditions, and to optimize their function, it is necessary 
to functionalize them with polymers, such as polyeth-
ylene glycol (Peg) or poly–(lactic-co-glycolic acid) 
(Plga).65 The Peg, for example, is one of the most 
commonly used polymers, and it has important func-
tions such as improving drug encapsulation and sub-
sequent release, and extending the circulation half-life 
of the nPs by preventing the opsonization process and 
avoiding the uptake by the reticuloendothelial system in 
vivo.56, 66 The HER2-targeted PLGA−PEG block copo-
lymer nPs, encapsulating Mnfe2o4 and doX, exhibit 
ultrasensitive detection by Mri, and excellent tumor 
growth retardation both in vitro and in vivo, with high 
specificity for breast cancer.52, 67 The SPio combined 
with Plga, and loaded with the anticancer Paclitaxel, 
is able to delay tumor growth in mouse xenograft mod-
els of colon carcinoma.68 The Pegylated fePt@fe2o3 
nPs, thanks to their hydrophobic oleic acid layer, are 
able to incorporate DOX. The specific release of DOX 
occurs with a ph-dependent mechanism, and it is fa-
vored by an acid ph, typical of tumor environment.65 
Pegylated nPs composed by geM-50-monophosphate 
and Gadolinium showed a higher anticancer efficacy 
in breast cancer xenograft mouse model compared to 
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MRI gene therapy
The aim of gene therapy is the replacement, the si-
lencing or the regulation of a pre-existing defective 
gene through the administration of genetic material. 
nucleic acid internalization is subjected to degrada-
tion by immune system, thus reducing gene therapy ef-
ficacy.53, 77 Both viral and non-viral vectors have been 
developed to promote genetic materials delivery in vivo. 
Viral vectors, even if effective in gene delivery, often 
cause an immune response.77 To overcome this issue, 
MnPs can be functionalized to obtain their accumula-
tion in tumors and to achieve gene delivery by magnetic 
field application.52, 53 in order to produce a successful 
effect, it is necessary that such loaded-nPs can pene-
trate into the cell nucleus, before releasing the genetic 
material. This goal is obtained through conjugation of 
peptides.64 The concentration of MnPs in tumor mass 
and gene transfer by means of a magnetic field is called 
“magnetofection”, which has the advantage of realizing 
a specific-site therapy, and it is not applicable to “dif-
fuse” tumors.78
Small interfering rnas (sirnas), has been recently 
one of the main protagonists in the scenario of gene 
therapy. sirnas are able to silence pathways that are 
up-regulated in a cancer cell, but when sirnas are in-
jected intravenously, they are rapidly degraded.79 for 
this reason, and to improve the transduction efficacy of 
sirnas, different systems have been developed. Poly-
ethyleneimine (Pei) possesses large amounts of func-
tionalized amine groups that allow building up complex 
molecules with nucleic acids that can be used to deliver 
sirna.79
Tripeptide arginine glycine aspartic acid (rgd)-
PEG-g-PEI-SPIO exhibited high efficacy as MRI con-
trast agent as well as inhibitor of tumor growth in a 
mouse model of hepatocellular carcinoma, suppressing 
survivin, an anti-apoptotic protein overexpressed in this 
histologic type.79 nevertheless, Pei combined with nPs 
showed high toxicity. A disulfide-based polycation (SS-
Pei), incorporated in SPio, represented a useful strat-
egy for gene delivery and Mri imaging with reduced 
toxicity, in tumor bearing mice.80
Tumor suppression through gene therapy can be car-
ried out through the down-regulation of angiogenic 
factors, which promote tumor aggressiveness and me-
tastasis capability. The Pegylated magnetic mesopo-
rous silica nPs Pei-capped, conjugated with fusogenic 
photothermal hyperthermia, leading to an optimal ther-
apeutic efficiency.56 The PEG-modified GO@Gd com-
bined with doX showed ability to detect tumor loca-
tion on Mri, and high photothermal-chemotherapeutic 
efficacy with low toxicity, in a xenograft mouse model 
of sarcoma.59
Magnetic hyperthermia treatment employs an al-
ternating magnetic field to raise the temperature of 
the nPs. Since cancer cells are more sensitive to heat 
compared to normal cells, this treatment appears to be 
safe and in some way specific for tumor tissues, even 
if specific magnetic frequencies should be selected to 
avoid healthy tissue damage. however, to ensure a suc-
cessful outcome, i.e. a temperature rise able to produce 
cell death, a sufficient amount of MNPs should be ac-
cumulated into the tumor.73
recently, a liquid phase system composed by fe3o4 
nPs, calcium phosphate cement and Peg-600 has been 
developed, which can be injected directly into the tumor 
mass in vivo. This material, once inside the tumor mass, 
turns into solid phase, thus avoiding the spread to the sur-
rounding tissues. By applying an alternating magnetic 
field, this complex generates heat causing the death of 
cancerous cells.74 another advantage of magnetic hyper-
thermia is the increasing drug penetration due to destruc-
tion of the extracellular matrix.64 The doX-loaded mul-
tifunctional liquid to solid phase transitional magnetic 
material can generate heat when exposed to alternating 
magnetic field. This method improved both thermal abla-
tion and the doX delivery. in fact, doX release percent-
age and rate was higher in tumor xenograft mice exposed 
to alternating magnetic field than in non-exposed mice.75
in spite of PTT and magnetic hyperthermia being 
among the most recently tumor ablation methods, each 
of them is characterized by its own main disadvantages. 
for PTT, high doses of nir laser irradiation can dam-
age surrounding tissues, whereas for magnetic hyper-
thermia, high concentrations of nPs are required, which 
may produce systemic side effects. These drawbacks 
might be overcome by dual modality treatment using 
ionPs, which show both magnetic and thermal fea-
tures, as demonstrated in tumor bearing mice. espinosa 
et al. in 2016 through an alternating magnetic field and 
nir laser irradiation at a wavelength of 808 nm, dem-
onstrated that it is possible to amplify hyperthermia 2 to 
5 fold compared with magnetic stimulation alone, with 
complete tumor eradication in vivo.76
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nite amount of nPs in the tumor are required, which 
is limited by the maximum tolerated dose, and an in-
creased magnetic field, which may produce a damaging 
heat level in the surrounding tissues.66 in a similar way, 
also magnetofection is limited by the maximum toler-
ated dose. Taken together, these results encourage the 
implementation of methods for theranostics, in order to 
minimize the systemic and toxic effects induced by con-
ventional chemotherapies.
A new drug delivery method: 
MRI-guided focused ultra sound
a major goal of pharmacology is to achieve adequate 
concentration of the drug in the site of disease by limit-
ing toxicity to normal tissues.
it has long been understood that the local drug de-
livery with real-time imaging is a promising strategy in 
achieving this goal.87
ultrasound and Magnetic resonance imaging (Mri) 
play an important role in this field.88 ultrasound, as we 
have demonstrated, when used in conjunction with mi-
crobubbles is a very useful method for drug delivery, 
allowing the release of biological drugs from the ve-
hicle at the site of interest thereby increasing local per-
meability of the cell membrane.16-18, 21 however, after 
the outburst of the microbubbles and the release of the 
drug the hyper-echogenicity disappears. Therefore, ul-
trasound imaging can only be used to follow and image 
the microbubbles at the target disease site, but distri-
bution and further monitorization of the delivered drug 
can not be determined.
it is possible instead by using Mri to not only deliver 
the drug, but also to monitor and follow biodistribution 
of the delivered drug. Mri offers several advantages, 
for example, it is completely non-invasive, it has a high 
spatial resolution, a high variety of biomarkers, and a 
temporal resolution sufficient to measure changes in the 
distribution of the drug.
The best way to monitor the pharmacodynamics and 
pharmacokinetics of a drug is to follow the same drug 
using contrast agents conjugated with the drug itself. a 
new approach includes loading the drug with the con-
trast agent in the same delivery system. for example, 
loading of MnSo4/doxorubicin in liposomes to monitor 
in vivo the concentration and the release of the drug has 
been recently explored.89
peptide (Kala)-functionalized sirna delivery sys-
tem, showed a high anti-tumor efficacy through VEGF 
down-regulation in a mouse model of ovarian cancer.81 
finally, chitosan nPs have been developed to obtain 
optimal results in gene therapy, due to the chitosan mo-
lecular weight and to nPs degree of deacetylation; how-
ever, they should be tested in further in vivo studies 82 to 
determine their efficacy and safety.
Toxicity of MRI nanoparticles for 
theranostic applications
The principal aim of nanotheranostics is to improve 
and to anticipate treatment, and response, while mini-
mizing systemic toxicity and side effects. gadolinium, 
which is commonly used as contrast agent in clinical 
imaging, may be toxic in some patients, particularly 
with some insufficiency and it is also harmful to the 
environment.56 on the other hand, the toxicity of nPs 
is highly dependent on structural properties, dosage, 
solubility, surface chemistry, administration route, bio-
degradability, pharmacokinetics, and biodistribution.83 
The cytotoxic effect of MnPs is mainly due to the pro-
duction of reactive species of oxygen that induce cell 
death, when the dosage exceeds 100μg/mL.83 however, 
reactive species of oxygen may be desired to kill cancer 
cells.84 MnPs do not generate particular toxic effects 
in vivo, as showed by the absence of major changes in 
mice bodyweight.66, 67, 70, 72, 81
in order to reduce as much as possible adverse effects 
of nPs, their production was directed towards compo-
nents already existing in nature, such as ionPs.56 how-
ever, in vivo studies about the toxicity mechanism of 
IONPs are still conflicting.85 The ionPs administered 
in animals showed different toxicity degrees depend-
ing on nPs size, crystalline phase and dissolution rate, 
administered dose, and age or preexistent pathological 
state of the animals analyzed.85
Studies on SPio showed that, in addition to the phys-
ical and chemical composition and dose of nPs, dif-
ferent cell types show different degree of cytotoxicity. 
indeed, cardiac cells do not suffer any toxic effect from 
SPio, whereas SPio produced severe disruption of the 
actin cytoskeleton in renal and cerebral cells in vivo.86 
additionally, Pei and Peg conjugations have demon-
strated reduced in vivo toxicity.66, 78
In order to generate magnetic hyperthermia a defi-
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been proposed more than 30 years ago, when yatvin et 
al. in 1978 described the effect of hyperthermia on the 
liposomal carrier.91
But only in 2006, it has been introduced the use of 
liposomes in combination with hifu. in particular, 
doxorubicin loaded liposomal particles (doxil) in com-
bination with hifu have been used in a mouse model 
of breast cancer.92 in this particular study, the doxoru-
bicin loaded liposomal particles did not reach a thera-
peutic advantage since doxil was not thermosensitive; 
however, it was shown that hifu induced an increase 
in the permeability of macromolecules in tumors.
The following year the first study on thermosensitive 
liposomes and hifu was presented.93 The same team 
then developed thermosensitive liposomes Mri-labeled 
to induce liposomes to release the drug locally and to 
improve therapeutic profiles.
a further application of hifu was the combination 
with microbubbles to enhance the permeability of bio-
active molecules across the blood-brain barrier (BBB). 
in a 2002 study, it was observed that the hifu can alter 
the BBB, inducing a reversible disturbance in a targeted 
area,94 and microscopy showed that the architecture of 
the brain was completely maintained after treatment.
The Mri-guided fuS method could be used for vari-
ous therapeutic applications. for example, for the thera-
peutic delivery of large molecules that do not permeate 
the BBB or to deliver magnetic nanoparticles of iron 
oxide (MnPs) conjugated with an antineoplastic agent 
such as epirubicin.95 The MnPs when delivered with 
fuS have favorable characteristics to Mr imaging, 
demonstrating considerable accumulation in the brain 
of rats of both the Mn particles and epirubicin.
The same method could also be used for transferring 
exogenous genes in the central nervous system, or for 
delivering therapeutic stem cells for the treatment of 
neurodegenerative diseases, brain injury, and stroke.
This strategy for drug delivery is a promising clinical 
approach and can be translated to the clinic as Magnetic 
resonance-guided focused ultrasound (MrgfuS). 
The main delivery vehicles described until now are 
thermosensitive liposomes and microbubbles, but new 
research should aim to use other nanocarriers like mi-
celles, because the combination of micelle with fuS 
could substantially enhance their delivery in target tis-
sues. nonetheless, the biological effects of fuS in the 
presence or absence of carriers will require more thor-
another Mri application is the focal drug delivery 
through Mri-guided focused ultrasound.90 The term fo-
cal drug delivery has been introduced to describe focal 
targeting of drugs in tissues with the aid of imaging and 
focused ultrasound. The focused ultrasound (fuS) or 
therapeutic high intensity focused ultrasound (hifu) is 
a non-invasive medical treatment that allows focusing 
the ultrasound at a given point of the body. The energy 
levels transported by the ultrasonic beam are of differ-
ent orders of magnitude compared to those of diagnostic 
standards. These ultrasound beams may be delivered to 
a small volume sparing surrounding tissue. The main 
effects of the fuS beam are heat, mechanical effects, 
cavitation, and chemical effects. heat is the most com-
mon physical effect generated by sound waves into the 
body. When the heat generation rate is higher than the 
dissipation rate of the body, the body temperature in-
creases significantly; temperatures higher than 43 °c, if 
sustained for a prolonged period can be harmful. The 
mechanical effects, such as breaking of bonds, may oc-
cur when the amplitude wave ultrasound is significantly 
high. cavitation occurs when the ultrasound beam of 
sufficient intensity passes through a liquid in which gas 
bubbles have been generated; the alternation of high 
and low pressure periods force the bubbles to contract 
and expand. during contraction, the internal pressure 
of the bubble increases, and the temperature can reach 
10.0000 °c, causing the explosion of the bubble which 
liberates a large amount of energy, although for small 
distances (microns). The tissues and cells in the vicinity, 
accordingly, can be damaged.
The guide and monitoring through real-time imaging 
ensures that the fuS beam is focused on the area during 
the procedure and Mri imaging modalities are current-
ly used for driving and monitoring the fuS treatment.
The combination of high-intensity focused ultra-
sound with high-resolution Mr guidance has created 
a system able to produce the destruction of the tissues 
deep within solid organs, without any invasion. Mri al-
lows precise targeting of ultrasound and also provides 
an accurate real-time thermal mapping. nanocarriers 
and microbubbles can also be used for drug delivery be-
cause they provide a better contrast.
in fact, using nanocarriers sensitive to mechanical 
forces and/or sensitive to temperature, the contents can 
be released locally.
Thermosensitive liposomes for drug delivery have 
Th
is
 d
oc
um
en
t i
s 
pr
ot
ec
te
d 
by
 in
te
rn
a
tio
na
l c
op
yr
ig
ht
 la
w
s.
N
o 
ad
di
tio
na
l r
ep
ro
du
ct
io
n 
is 
au
th
or
ize
d.
It 
is
 p
er
m
itt
ed
 fo
r 
pe
rs
on
al
 u
se
 to
 d
ow
n
lo
ad
 a
nd
 s
av
e
 o
n
ly 
on
e 
file
 a
nd
 p
rin
t o
nl
y 
on
e 
co
py
 o
f t
hi
s 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 m
ak
e
 a
dd
itio
na
l c
op
ie
s
(ei
the
r s
po
rad
ica
lly
 o
r s
ys
te
m
at
ica
lly
,
 
e
ith
er
 p
rin
te
d 
or
 e
le
ct
ro
ni
c) 
of 
the
 A
rtic
le
 fo
r 
a
ny
 p
ur
po
se
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 d
ist
rib
u
te
 th
e 
el
ec
tro
ni
c 
co
py
 o
f t
he
 a
rti
cl
e 
th
ro
ug
h 
on
lin
e 
in
te
rn
e
t a
nd
/o
r i
nt
ra
n
e
t f
ile
 s
ha
rin
g 
sy
st
em
s,
 
e
le
ct
ro
ni
c 
m
ai
lin
g 
or
 a
ny
 o
th
er
m
e
a
n
s 
w
hi
ch
 m
ay
 a
llo
w
 a
cc
e
ss
 to
 th
e 
Ar
tic
le
.
Th
e 
us
e 
of
 a
ll 
or
 a
ny
 p
ar
t o
f t
he
 A
rti
cl
e 
fo
r 
a
ny
 C
om
m
er
cia
l U
se
 is
 n
ot
 p
er
m
itt
ed
.T
he
 c
re
at
io
n 
of
 d
er
iva
tiv
e
 w
o
rk
s 
fro
m
 th
e 
Ar
tic
le
 is
 n
ot
 p
er
m
itt
ed
.T
he
 p
ro
du
ct
io
n 
of
 re
pr
in
ts
 fo
r 
pe
rs
on
al
 o
r c
om
m
er
cia
l u
se
 is
n
o
t p
er
m
itt
ed
.I
t i
s 
no
t p
er
m
itt
ed
 to
 re
m
ov
e,
 
co
ve
r,
 
ov
e
rla
y, 
o
bs
cu
re
,
 
bl
oc
k,
 o
r c
ha
ng
e 
an
y 
co
py
rig
ht
 n
ot
ice
s 
or
 te
rm
s 
o
f u
se
 w
hi
ch
 th
e 
Pu
bl
is
he
r m
ay
 p
os
t o
n 
th
e 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 fr
a
m
e
 o
r 
u
se
 fr
a
m
in
g 
te
ch
ni
qu
es
 to
 e
nc
lo
se
 a
ny
 tr
a
de
m
ar
k,
 lo
go
,
o
r 
o
th
er
 p
ro
pr
ie
ta
ry
 in
fo
rm
a
tio
n 
of
 th
e 
Pu
bl
is
he
r.
greco adVanceS in Molecular Preclinical TheraPy MediaTed By iMaging
92 The QuarTerly Journal of nuclear Medicine and Molecular iMaging March 2017
with potential to translate from the laboratory into the clinic. discov 
Med 2011;11:46-56.
20. Paefgen V, doleschel d, Kiessling f. evolution of contrast agents 
for ultrasound imaging and ultrasound-mediated drug delivery. front 
Pharmacol 2015;6:197.
21. nande r, howard cM, claudio PP. ultrasound-mediated oncolytic 
virus delivery and uptake for increased therapeutic efficacy: State of 
art. oncolytic Virother 2015;4:193-205.
22. carson ar, Mctiernan cf, lavery l, grata M, leng X, Wang J, et al. 
ultrasound-targeted microbubble destruction to deliver sirna cancer 
therapy. cancer res 2012;72:6191-9.
23. livney yd, assaraf yg. rationally designed nanovehicles to over-
come cancer chemoresistance. adv drug deliv rev 2013;65:1716-
30.
24. husseini ga, Velluto d, Kherbeck l, Pitt Wg, hubbell Ja, chris-
tensen da. investigating the acoustic release of doxorubicin from 
targeted micelles. colloids Surf B Biointerfaces 2013;101:153-5.
25. Sanson c, diou o, Thevenot J, ibarboure e, Soum a, Brulet a, et 
al. doxorubicin loaded magnetic polymersomes: Theranostic na-
nocarriers for mr imaging and magneto-chemotherapy. acS nano 
2011;5:1122-40.
26. hughes MS, Marsh Jn, Zhang h, Woodson aK, allen JS, lacy eK, 
et al. characterization of digital waveforms using thermodynamic 
analogs: detection of contrast-targeted tissue in vivo. ieee Trans ul-
trason ferroelectr freq control 2006;53:1609-16.
27. Krafft MP, riess Jg. Highly fluorinated amphiphiles and colloidal 
systems, and their applications in the biomedical field. A contribution. 
Biochimie 1998;80:489-514.
28. Piao l, li h, Teng l, yung Bc, Sugimoto y, Brueggemeier rW, et 
al. human serum albumin-coated lipid nanoparticles for delivery of 
sirna to breast cancer. nanomedicine 2013;9:122-9.
29. chiappetta da, Sosnik a. Poly(ethylene oxide)-poly(propylene ox-
ide) block copolymer micelles as drug delivery agents: improved 
hydrosolubility, stability and bioavailability of drugs. eur J Pharm 
Biopharm 2007;66:303-17.
30. diaz de la rosa Ma, husseini ga, Pitt Wg. comparing microbub-
ble cavitation at 500 khz and 70 khz related to micellar drug delivery 
using ultrasound. ultrasonics 2013;53:377-86.
31. Kwon gS. Polymeric micelles for delivery of poorly water-soluble 
compounds. crit rev Ther drug carrier Syst 2003;20:357-403.
32. le garrec d, gori S, luo l, lessard d, Smith dc, yessine Ma, et al. 
Poly(n-vinylpyrrolidone)-block-poly(d,l-lactide) as a new polymeric 
solubilizer for hydrophobic anticancer drugs: in vitro and in vivo 
evaluation. J control release 2004;99:83-101.
33. Michaelis K, hoffmann MM, dreis S, herbert e, alyautdin rn, 
Michaelis M, et al. covalent linkage of apolipoprotein e to albumin 
nanoparticles strongly enhances drug transport into the brain. J Phar-
macol exp Ther 2006;317:1246-53.
34. Huynh E, Leung BY, Helfield BL, Shakiba M, Gandier JA, Jin CS, et 
al. in situ conversion of porphyrin microbubbles to nanoparticles for 
multimodality imaging. nat nanotechnol 2015;10:325-32.
35. Blanco e, Shen h, ferrari M. Priciples of nanoparticles design for 
overcoming biological barriers to drug delivery. nat Biotechnology 
2015;33.
36. Jain a, Jain SK. Pegylation: an approach for drug delivery. a review. 
crit rev Ther drug carrier Syst 2008;25:403-47.
37. rodriguez Pl, harada T, christian da, Pantano da, Tsai rK, 
discher de. Minimal “self” peptides that inhibit phagocytic clear-
ance and enhance delivery of nanoparticles. Science 2013;339:971-5.
38. Parodi a, Quattrocchi n, Van de Ven al, chiappini c, evangelo-
poulos M, Martinez Jo, et al. Synthetic nanoparticles functionalized 
with biomimetic leukocyte membranes possess cell-like functions. 
nat nanotechnol 2013;8:61-8.
39. gentile f, chiappini c, fine d, Bhavane rc, Peluccio MS, cheng 
MM, et al. The effect of shape on the margination dynamics of non-
neutrally buoyant particles in two-dimensional shear flows. J Bio-
mech 2008;41:2312-8.
40. Shah S, liu y, hu W, gao J. Modeling particle shape-dependent dy-
namics in nanomedicine. J nanosci nanotechnol 2011;11:919-28.
ough examination, in particular regarding the long-term 
effects on normal tissues to be evaluated in preclinical 
studies to design a safe and effective fuS drug treat-
ment regimens.
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